Radiofrequency ablation of paroxysmal atrial fibrillation: factors determining long-term clinical efficacy

Arq Bras Cardiol. 2008 Feb;90(2):112-8. doi: 10.1590/s0066-782x2008000200008.
[Article in English, Portuguese]

Abstract

Background: Most of the studies on this subject have reported predictors of recurrence of atrial fibrillation after catheter ablation with relatively short follow-up periods.

Objective: To retrospectively evaluate predictors of long-term recurrence of paroxysmal atrial fibrillation (AF) in patients undergoing pulmonary vein isolation following one single procedure.

Methods: The authors studied a total of 139 patients (102 men; mean age of 55 +/- 12 years) undergoing radiofrequency ablation using the ostial or extra-ostial techniques for left atrial approach, combined or not with cavotricuspid isthmus ablation (CTI). Pre, intra and post-ablation variables were evaluated using univariate and multivariate analyses to determine the predictors of recurrence of AF after one procedure.

Results: After a 33 +/- 12-month follow-up, we observed that a longer time of history of AF, use of more antiarrhythmic drugs, and recurrence of AF within 60 days post-procedure increased the risk of long-term recurrence of AF. On the other hand, the association of atrial flutter and concomitant CTI ablation reduced the risk of recurrence of AF.

Conclusion: Clinical variables such as time of history of AF and a larger number of antiarrhythmic drugs already used influenced the outcomes of catheter ablation. In patients with associated atrial flutter, simultaneous CTI block significantly reduced the long-term recurrence of atrial fibrillation.

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / surgery
  • Atrial Flutter / surgery
  • Catheter Ablation* / methods
  • Epidemiologic Methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Veins / surgery*
  • Recurrence
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents